5 completed, 1 enrolling by invitation, 1 withdrawn. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Enrolling by invitation 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Enrolling by invitation 1 |
| Phase 3 | 1 | Completed 1 |
Follow Iris Diseases: new trials by email Literature Review of Iris Diseases trials Research Report on Iris Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma | Phase 1 / Phase 2 | Enrolling by invitation | Stanford University | 90 | 2026-09-10 | 2026-10-13 |
| RAFT - Clinical Trial of RAFT for Aniridia Related Keratopathy RAFT-OS - Aniridia | Phase 1 / Phase 2 | Completed | University College, London | 9 | 2021-07-28 | 2025-04-30 |
| A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia Ataluren - Aniridia | Phase 2 | Withdrawn | PTC Therapeutics | 2018-12-31 | 2019-10-07 | |
| Study of Ataluren in Participants With Nonsense Mutation Aniridia Ataluren, Placebo - Aniridia | Phase 2 | Completed | PTC Therapeutics | 39 | 2016-01-31 | 2022-05-27 |
| A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma AR-12286 - Exfoliation Syndrome, Ocular Hypertension | Phase 2 | Completed | Robert Ritch, MD, LLC. | 10 | 2013-09-01 | 2018-11-16 |
| Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery? Triesence, balanced salt solution BSS - Glaucoma | Phase 2 / Phase 3 | Completed | Wills Eye | 77 | 2009-02-01 | 2018-07-10 |
| Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis Daclizumab - Anterior Uveitis, Arthritis, Juvenile Idiopathic | Phase 2 | Completed | National Eye Institute (NEI) | 6 | 2005-08-01 | 2017-01-30 |
Aniridia (3) · Exfoliation Syndrome (3) · Glaucoma, Open-Angle (3) · Glaucoma (2) · Arthritis, Juvenile (1) · Glaucoma, Angle-Closure (1) · Glaucoma, Neovascular (1) · Iritis (1) · Low Tension Glaucoma (1) · Ocular Hypertension (1) · Uveitis, Anterior (1)
Eye Diseases (7) · Uveal Diseases (7) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Eye Abnormalities (3) · Eye Diseases, Hereditary (3) · Genetic Diseases, Inborn (3) · Ocular Hypertension (2) · Arthritis (1) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Glaucoma (1) · Immune System Diseases (1) · Joint Diseases (1)
ataluren (2) · AR-12286 (1) · Daclizumab (1) · Hanks Balanced Salt Solution (1) · Insulin (1) · Triamcinolone (1)
PTC Therapeutics (2) · National Eye Institute (NEI) (1) · Robert Ritch, MD, LLC. (1) · Stanford University (1) · University College, London (1) · Wills Eye (1)
United States (5) · Canada (1) · United Kingdom (1)
Jeffrey L Goldberg, MD PhD (1) · Julie Daniels (1) · Marlene R Moster, MD (1) · Quintus Ngumah, OD, PhD (1) · Sajjad Ahmad (1)